# US 2020/0400692 A1 · Systems, methods, and biomarkers for determining the metabolic state of red blood cells and platelets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0400692 A1
- Document ID: US20200400692A1
- Status: Published application
- Kind: A1
- Application number: 16/752,155
- Filed: 2020-01-24
- Published: 2020-12-24
- Earliest claimed: 2014-05-23
- Assignees: University of Iceland, Center for Systems Biology
- Applicants: University of Iceland, Center for Systems Biology
- Inventors: Giuseppe PAGLIA; Sirus PALSSON; Aarash BORDBAR
- Web page: https://patentgrep.com/patent/US20200400692A1

## CPC

- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- G01N 33/56966: {Animal cells}
- G01N 33/57595: {involving intracellular compounds}
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- G01N 2030/8822: {involving blood}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are methods, biomarkers, systems, compositions and kits for determining the phase or metabolic state (e.g. First Phase, Second Phase, or Third Phase) of a red blood cell (RBC) sample or for determining the phase or metabolic state (e.g., First Phase or Second Phase) of a platelet (PLT) cell sample. The methods disclosed herein are related to the use of isolated RBC sample or isolated PLT sample and analytical tools for providing information that is relevant to the phase or metabolic state of the RBC sample or the PLT sample. The system disclosed herein utilizes isolated RBC sample or isolated PLT sample and at least one analytical tool or an output from the at least one analytical tool. The compositions and kits described herein utilize RBC samples or PLT samples, including compositions in a form that allows for analysis of the RBC sample or the PLT sample.

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 74

A method of determining whether a blood sample is safe for transfusion into a subject, the method comprising:
a. contacting the blood sample with one or more reagents in a testing module of a device; and
b. detecting a concentration of hypoxanthine in the blood sample using the device, wherein the blood sample is safe for transfusion into the subject if the concentration of hypoxanthine is from 0 mM to about 0.1 mM, and the blood sample is not safe for transfusion into the subject if the concentration of hypoxanthine is greater than about 0.1 mM.

### Claim 75 (depends on 1)

The method of claim 1, wherein the testing module is operatively connected to an inner wall of a storage container configured to store the blood sample.

### Claim 76 (depends on 1)

The method of claim 1, wherein the detecting the concentration of hypoxanthine is performed by the testing module using a colorimetric assay or a luminescent assay.

### Claim 77 (depends on 1)

The method of claim 1, further comprising separating the blood sample into an extracellular portion and an intracellular portion with the reagents of the testing module, wherein the detecting the concentration of hypoxanthine comprises analyzing the extracellular portion of the blood sample.

### Claim 78 (depends on 1)

The method of claim 1, wherein the blood sample is a red blood sample.

### Claim 79 (depends on 1)

The method of claim 1, wherein the blood sample comprises red blood cells and an additive solution.

### Claim 80 (depends on 1)

The method of claim 1, wherein the blood sample is an extracellular blood sample.

### Claim 81 (depends on 1)

The method of claim 1, further comprising detecting a concentration of inosine, adenine, pyruvate, glucose, lactate, Na+, K+, or any combination thereof in the blood sample.

### Claim 82 (depends on 1)

The method of claim 1, further comprising administering the blood sample to a subject in need thereof.

### Claim 83

A method of administering a blood sample to a subject in need thereof, the method comprising:
a. measuring a level of one or more biomarkers in the blood sample, wherein the one or more biomarkers comprises hypoxanthine, or a ratio of hypoxanthine and adenine, or a combination thereof;
b. assigning a metabolic state of the blood sample based on the level of the one or more biomarkers measured in (a), wherein the metabolic state assigned is one of:
(i) a First Phase when the concentration of hypoxanthine, or the ratio of hypoxanthine:adenine, or a combination thereof matches the values on a control indicated for the First Phase;
(ii) a Second Phase when the concentration of hypoxanthine or the ratio of hypoxanthine:adenine, or a combination thereof matches the values on a control indicated for the Second Phase; or
(iii) a Third Phase when the concentration of hypoxanthine or the ratio of hypoxanthine:adenine, or a combination thereof matches the values on a control indicated for the Third Phase; and
c. if the metabolic state of the blood sample that is assigned in (b) is the First Phase or the Second Phase, administering the blood sample to the subject; and
d. if the metabolic state of the blood sample that is assigned in (b) is the Third Phase, then identifying the blood as unsafe for administration to the subject.

### Claim 84 (depends on 10)

The method of claim 10, wherein a ratio of hypoxanthine:adenine in the range of 0 to about 1.0 is associated with the First Phase, a ratio in the range of about 1.0 to about 16 is associated with the Second Phase, and a ratio greater than about 16 is associated with the Third Phase.

### Claim 85 (depends on 10)

The method of claim 10, wherein a concentration of hypoxanthine in the range 0 mM to about 0.1 mM is associated with both the First Phase and the Second Phase and a concentration of hypoxanthine greater than 0.1 mM is associated with the Third Phase.

### Claim 86 (depends on 10)

The method of claim 10, wherein assigning the metabolic state in (b) is performed using a colorimetric assay or a luminescent assay.

### Claim 87 (depends on 10)

The method of claim 10, wherein the control comprises a signature profile of the one or more biomarkers over time.

### Claim 88 (depends on 10)

The method of claim 10, wherein the one or more biomarkers further comprises a concentration of inosine, a concentration of adenine, a ratio of glucose:lactate, a ratio of Na+:K+, a ratio of pCO2:pH, a ratio of inosine:adenine, a concentration of pyruvate, or a combination thereof.

### Claim 89

A method comprising administering a blood sample to an individual that is assigned a metabolic state of a First Phase or a Second Phase based on a level of one or more biomarkers measured in the blood sample, wherein the one or more biomarkers comprises hypoxanthine, or a ratio of hypoxanthine and adenine, or a combination thereof.

### Claim 90 (depends on 16)

The method of claim 16, wherein the blood sample is assigned a metabolic state of a First Phase, a Second Phase, or a combination thereof if the level of hypoxanthine measured is from 0 mM to about 0.1 mM.

### Claim 91 (depends on 16)

The method of claim 16, wherein the blood sample is assigned a metabolic state of a First Phase if the ratio of hypoxanthine:adenine measured is from 0 to about 1.0.

### Claim 92 (depends on 16)

The method of claim 16, wherein the blood sample is assigned a metabolic state of a Second Phase if the ratio of hypoxanthine:adenine measured is from about 1.0 to about 16.

### Claim 93 (depends on 16)

The method of claim 16, wherein the one or more biomarkers further comprise a concentration of inosine, a concentration of adenine, a ratio of glucose:lactate, a ratio of Na+:K+, a ratio of pCO2:pH, a ratio of inosine:adenine, a concentration of pyruvate, or a combination thereof.
